Is it safe for a patient who drinks alcohol on weekends while being treated with Spravato (esketamine) nasal spray to continue drinking, or should they avoid alcohol because it may reduce the medication’s effectiveness and increase side effects?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Alcohol Use During Spravato Treatment: Clear Guidance

Patients receiving Spravato (esketamine) treatment should avoid alcohol consumption entirely, as alcohol is a central nervous system depressant that can dangerously amplify Spravato's sedative and dissociative effects, increase the risk of respiratory depression, and potentially undermine the medication's antidepressant efficacy.

Why Alcohol and Spravato Don't Mix

Safety Concerns Are Paramount

The FDA label for Spravato explicitly warns about combining the medication with central nervous system (CNS) depressants, which includes alcohol 1. Here's what happens when you mix them:

  • Amplified sedation and dissociation: Spravato already causes sleepiness, dizziness, feeling disconnected from reality, and can impair breathing. Alcohol magnifies all of these effects 1
  • Respiratory depression risk: The combination can lead to dangerous slowing or stopping of breathing 1
  • Impaired judgment and safety: You're already required to have someone drive you home after Spravato and avoid operating machinery until the next day after restful sleep. Adding alcohol creates compounded impairment 1

Treatment Effectiveness at Stake

Beyond immediate safety, weekend drinking undermines your treatment goals:

  • Alcohol is a depressant: It directly worsens depressive symptoms and works against what Spravato is trying to accomplish. The 2022 VA/DoD guidelines on major depressive disorder emphasize that esketamine is reserved for patients with treatment-resistant depression who haven't responded to multiple adequate antidepressant trials 2—this is serious treatment for serious depression, and alcohol sabotages it

  • Substance use as a barrier: Research shows that substance use disorder is associated with lower likelihood of initiating and completing esketamine treatment 3. Even weekend drinking patterns can interfere with treatment adherence and outcomes

The Clinical Reality

Spravato requires mandatory 2-hour monitoring after each dose specifically because of risks like sedation, dissociation, and respiratory problems 1. The medication is only available through a restricted REMS program due to these safety concerns and abuse potential 1. Adding alcohol to this equation is medically inadvisable.

What About "Just Weekends"?

Some patients rationalize that drinking only on weekends—when they're not taking Spravato—is acceptable. This thinking is flawed:

  • Alcohol's depressant effects on mood persist beyond acute intoxication
  • Regular alcohol use, even if "moderate," can reduce treatment response in depression
  • The 2024 ESC guidelines recommend limiting alcohol to less than 100g/week (roughly 7 standard drinks), and preferably avoiding alcohol entirely for best health outcomes 4—this applies even more strongly when treating serious psychiatric conditions

Practical Recommendations

For patients currently drinking on weekends while on Spravato:

  1. Stop alcohol consumption entirely during the active treatment phase (induction and maintenance)
  2. If alcohol use disorder is present, address this before or concurrently with Spravato treatment—guidelines support medications like acamprosate or baclofen for maintaining abstinence 5
  3. Engage in psychosocial support for alcohol cessation, including brief interventions, motivational interviewing, or group therapy 5
  4. Understand that continued alcohol use may be grounds for discontinuing Spravato treatment due to safety concerns and reduced likelihood of benefit

Common Pitfalls to Avoid

  • Don't minimize "social drinking": Any alcohol use during Spravato treatment carries risk
  • Don't assume weekend drinking is safe because it's not on treatment days—the effects are cumulative
  • Don't ignore substance use patterns: If a patient is drinking regularly despite knowing they shouldn't, this signals a need for addiction assessment and intervention 5

The Bottom Line

Alcohol abstinence is non-negotiable during Spravato treatment. The combination poses immediate safety risks (respiratory depression, excessive sedation), undermines treatment efficacy, and contradicts the serious nature of treating treatment-resistant depression. If a patient cannot stop drinking, they may not be an appropriate candidate for Spravato at this time, and addressing the alcohol use should become the priority 1.

References

Related Questions

What is the recommended dosing schedule, monitoring requirements, and contraindications for initiating Spravato (esketamine) nasal spray in an adult with treatment‑resistant major depressive disorder?
How should I manage anxiety that began three days after receiving Spravato (esketamine) treatment?
Are there any medications that combine ketamine with an SSRI or other psychiatric medication?
Is an adult patient with a history of opioid dependence, bipolar disorder, ADHD, experiencing nightmares and auditory hallucinations, currently on buprenorphine/naloxone (Suboxone) awaiting extended‑release buprenorphine (Sublocade), aripiprazole, quetiapine, clonidine, atomoxetine, propranolol, prazosin, and tizanidine, eligible for Spravato (esketamine nasal spray)?
Can you provide comprehensive information on Spravato (esketamine) nasal spray, including its indications, dosing schedule, administration requirements, monitoring parameters, contraindications, and alternative treatment options?
In patients with large lobar intracerebral hemorrhage (>30 mL) with midline shift ≥5 mm and coma (Glasgow Coma Scale < 8), does combined hematoma evacuation and decompressive craniectomy improve functional outcomes compared with evacuation alone or craniectomy alone?
How often should leptospirosis prophylaxis be administered?
What are the benefits of cholecystectomy, preferably performed laparoscopically?
Does craniotomy improve survival and functional outcome in patients with traumatic brain injury?
What is the next treatment approach for a 47-year-old perimenopausal woman with menorrhagia and normal hormonal laboratory results?
What is the infusion duration for mycophenolate mofetil (CellCept) and basiliximab in adult heart transplantation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.